SpliSense is excited to share its most recent press release, announcing the successful completion a first-in-human, Phase 1 clinical trial of SPL84, the company’s lead anti sense oligonucleotide (ASO) product for the treatment of patients with CF, carrying the unmet 3849-splicing mutation.

Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on email
Scroll Up Skip to content